A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
for Chronic Inflammatory Demyelinating Polyneuropathy
31 locations incl. Homewood
Sponsor: Sanofi
Sex: All·Age: 18+
Code: NCT06290141·Phase 3·Recruiting·Listed Mar 2024